Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMV564 Alone and with Pembrolizumab in Advanced Solid Tumors
NCT04128423Phase 1Unknown
- Sponsor
- Amphivena Therapeutics
- Start
- Oct 2019
- Primary completion
- Dec 2021
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label trial of AMV564 in solid tumor (advanced stage) (2 arms), sponsored by Amphivena Therapeutics. Primary endpoints: Incidence of Treatment-Related Adverse Events at 19 months, Maximum Tolerated Dose at 6 months and 1 more. Status: unknown.
02
Drugs
AMV564
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04128423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128423.